Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men

Colin, J.; Cazals–Hatem, Dominique; Loriot, Marie‐Anne; Martinot‐Peignoux, Michèle; Pham, Bach Nga; Aupérin, Anne; Degott, Claude; Benhamou, Jean‐Pierre; Erlinger, S; Valla, Dominique; Marcellin, Patrick

doi:10.1002/hep.510290447

Cited by 406 publications

(283 citation statements)

References 30 publications

Supporting

Mentioning

260

Contrasting

Unclassified

Order By: Relevance

“…[29][30][31][32][33]43 The rate of clearance of HBeAg is much lower in Asian children (most of whom have normal ALT levels) 34,35 and in immunocompromised subjects. 28,44 The largest prospective follow-up study conducted in Alaska of 1,536 carrier children and adults, followed for 12 years, showed that spontaneous HBeAg clearance occurred in 45% of carriers in 5 years and in 80% after 10 years. 43 Similarly, 3-and 5-year HBeAg clearance rates of 50% and 70% were reported in untreated children with elevated ALT levels from Taiwan and Italy.…”

Section: Terminology and Natural History Of Chronic Hbv Infectionmentioning

confidence: 99%

“…Persons who are chronically coinfected with HBV and HCV may have more rapid progression of liver disease 85 and a higher risk of developing HCC than carriers with HBV infection only. 7 Individuals with HBV and HIV coinfection tend to have higher levels of HBV DNA, lower rates of spontaneous HBeAg seroconversion, 28,44 and more severe liver disease. 86 Hepatitis D virus (HDV) is a satellite virus, which is dependent on HBV for the production of envelope proteins.…”

Section: Terminology and Natural History Of Chronic Hbv Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Chronic hepatitis B

2001

View full text Add to dashboard Cite

PREAMBLEThese guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV). They are intended to suggest preferable approaches to the clinical management of chronic hepatitis B. The recommendations are flexible and are not intended as the only acceptable approach to management and treatment. As the appropriate course of treatment will vary in light of the relevant facts and circumstances surrounding each individual patient with chronic hepatitis B, guidelines are not intended to define the applicable standard of medical care and may be updated periodically as new information becomes available.These guidelines were developed under the auspices of, and approved by, the Practice Guidelines Committee of the American Association for the Study of Liver Diseases. They should be taken as guidelines and not "standards of care." Data used to support the recommendations made were obtained by a literature search of peer-reviewed articles concerning the natural history, diagnosis, and treatment of chronic hepatitis B. In addition, the proceedings of a recent National Institutes of Health workshop on the "Management of Hepatitis B" were considered in the development of these guidelines. 1 The strength of each recommendation is categorized based on the quality of evidence in the literature according to the rating system indicated in Table 1. 2

show abstract

Section: Terminology and Natural History Of Chronic Hbv Infectionmentioning

confidence: 99%

Section: Terminology and Natural History Of Chronic Hbv Infectionmentioning

confidence: 99%

Chronic hepatitis B

2001

View full text Add to dashboard Cite

show abstract

“…The main outcomes of interest were: HBsAg conversion to negative, adequately suppressed HBV DNA (defined as <3.3 log 10 copies/ml or <2000 IU/ml), undetectable HBV DNA (defined as HBV-DNA <1.3 log 10 copies/ml or <20 IU/ml) and undetectable HIV RNA (defined as <50 copies/ml). The Fisher exact test or 2 test was used to compare the proportion of patients with an event. The Wilcoxon signed rank test or paired t test was used to assess changes from baseline in selected laboratory markers.…”

Section: Discussionmentioning

confidence: 99%

“…1 The hepatitis B surface antigen (HBsAg) is over five times more prevalent among HIV-infected patients than in the general population. [2][3][4] In North America and Europe, more than half of HIVinfected men who have sex with men have evidence of past HBV infection, and 5-10% have chronic hepatitis B, which is defined as the persistence of HBsAg in serum for longer than 6 months. 5 C chronic hepatitis B is more likely to develop and persist after HBV in patients with HIV infection.…”

Section: Introductionmentioning

confidence: 99%

Treatment outcomes in a cohort of patients with chronic hepatitis B and human immunodeficiency virus co-infection in Mumbai, India

Isaakidis¹,

Mansoor²,

Zachariah³

et al. 2012

International Health

View full text Add to dashboard Cite

CitationTreatment outcomes in a cohort of patients with chronic hepatitis B and human immunodeficiency virus coinfection in Mumbai, India 2012, 4 (4) Treatment experiences with patients co-infected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in resource-limited settings remain poorly documented.This study aimed to evaluate the treatment outcomes in a cohort of HIV/HBV co-infected individuals receiving tenofovir/lamivudine (TDF/3TC)-based antiretroviral therapy (ART) in a programmatic setting in Mumbai, India. Additionally, a cross-sectional laboratory study was carried out measuring serologic and virologic parameters. A total of 57 patients who received TDF/3TC were included in the study. Of these, 52 (91%) were male and the mean age was 38.7 years. The median follow-up period was 16.8 months (IQR:7.9-37.9). Forty-three patients were included in the cross-sectional laboratory study, of whom 38 (67%) were HBeAg + positive. Four patients had serum HBsAg conversion to negative and had developed anti-HBs-antibodies. HBV-DNA became undetectable (<1.3 log 10 copies/ml or <20 IU/ml) in 35.5% and 75% of the HBeAg + and HBeAg − patients, respectively. Overall, 46.5% of patients had undetectable HBV-DNA and 90.7% had adequately suppressed HBV-DNA (<3.3 log 10 copies/ml or <2000 IU/ml). The median reduction in serum HBV-DNA was 6 log 10 copies/ml. In 29 patients (63%) HIV viral load was undetectable. Outcomes included seven (12%) deaths, four (7%) lost to follow-up, one (2%) transferred out and 45 (79%) alive and on treatment. In conclusion, good treatment outcomes were achieved in a cohort of HIV/HBV co-infected patients in India. In regions with a high HIV/HBV burden, all HIV-infected individuals should be tested for chronic hepatitis B. A TDF/3TC-backbone could be considered as first-line standardized ART regimen in these settings.

show abstract

“…HIV and HBV co-infection is common due to shared routes of transmission. This union is undesirable because HIV negatively impacts on all the phases of the natural history of HBV infection, leading to higher rates of HBV chronicity and replication in co-infected patients compared to those mono-infected by HBV [3,4].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of hepatitis B e antigen among human immunodeficiency virus and hepatitis B virus co-infected patients in Jos, Nigeria

Iroezindu

Daniyam

Agbaji

et al. 2013

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Human immunodeficiency virus (HIV) negatively impacts the natural history of hepatitis B virus (HBV) infection, including replication. We determined the prevalence of HBeAg in HIV/HBV co-infected patients compared to HBV mono-infected controls and further investigated the relationship between HBeAg seropositivity and the degree of HIV-induced immunosuppression in co-infected patients. Methodology: The study design was cross-sectional. One hundred HBsAg-positive HIV-infected adults and 100 age and sex matched HBsAg-positive HIV negative controls were consecutively recruited between May and November 2010. Relevant demographic and HBVrelated information was obtained. HBeAg was assayed by semi-quantitative third generation ELISA. The HIV/HBV co-infected patients also had CD4+ cell and HIV viral load quantification measured using flow cytometry and polymerase chain reaction techniques respectively. Results: In each group, the mean age was 34 ± 8 years and the majority (61%) was female. The prevalence of HBeAg was significantly higher among co-infected patients (n = 28; 28%) than in the controls (n = 15; 15%; p = 0.03). HBeAg seropositivity was independently associated with age < 40 years (AOR = 2.83, 95% = CI 1.29-6.17) and HIV seropositivity (AOR = 2.44, 95% C.I = 1.17-5.07). The prevalence of HBeAg was significantly higher in co-infected patients with CD4 cell count < 200 cell/µL (41.3%) compared to those with 200-499 cell/µL (18.6%) and ≥500 cell/µL (9.1%), p = 0.006. Conclusion: HIV/HBV co-infected patients have a significantly higher prevalence of HBeAg than HBV mono-infected individuals. HBVinfected patients should be routinely assessed for HBeAg, especially if they are co-infected with HIV.

show abstract

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men

Cited by 406 publications

References 30 publications

Chronic hepatitis B

Chronic hepatitis B

Treatment outcomes in a cohort of patients with chronic hepatitis B and human immunodeficiency virus co-infection in Mumbai, India

Prevalence of hepatitis B e antigen among human immunodeficiency virus and hepatitis B virus co-infected patients in Jos, Nigeria

Contact Info

Product

Resources

About